Seranova Bio

Seranova Bio is an early-stage biotech harnessing the therapeutic potential of naturally occurring autoantibodies. Its core innovation is the REAP (Rapid Exoproteome Antigen Profiling) platform, a high-throughput, barcoded yeast display system that sensitively detects autoantibodies against correctly folded extracellular proteins. By combining this rich dataset with machine learning via its Seravista engine, Seranova identifies autoantibody reactivities correlated with improved disease outcomes, which it then develops into novel biologic drugs. The company is backed by Foresite Capital and founded by Yale immunologist Dr. Aaron Ring, positioning it to build a pipeline of antibody therapeutics inspired by human immune responses.

REAP (Rapid Exoproteome Antigen Profiling): A massively multiplexed, barcoded yeast display platform that profiles autoantibody reactivities against correctly folded human extracellular and secreted proteins (the exoproteome). Combined with Seravista, a machine learning engine that correlates reactivity data with clinical outcomes to identify protective, therapeutically relevant autoantibodies.

Seranova competes in the broad fields of antibody therapeutics and AI/ML-driven drug discovery. It faces competition from large biopharma with internal discovery engines and numerous biotechs applying computational biology to target identification. Its key differentiation is the specific focus on the human exoproteome via its REAP technology to find functionally validated, protective autoantibody signatures, a niche not directly addressed by standard proteomic or genomic screening approaches.